

SUPPLEMENTARY MATERIAL

Exploring Vitiligo History and Mental Health Burden Among People Within EU5 Countries: Findings From the Global VALIANT Study

Khaled Ezzedine, MD, PhD,¹ John E. Harris, MD, PhD,² Iltefat H. Hamzavi, MD,³ Kristen Bibeau, PhD, MSPH,⁴ Jessy Gao, MA,⁴ Haobo Ren, PhD,⁴ Nanja van Geel, MD, PhD⁵

¹Henri Mondor University Hospital and Université Paris-Est Créteil Val de Marne, Paris, France;

²University of Massachusetts Chan Medical School, Worcester, MA, USA; ³Henry Ford Medical Center, Detroit, MI, USA; ⁴Incyte Corporation, Wilmington, DE, USA; ⁵Ghent University Hospital, Ghent, Belgium


Corresponding Author:

Khaled Ezzedine, MD, PhD

Email: khaled.ezzedine@aphp.fr


Figure S1. EU5 Patients (a) Not Actively Using Treatment and (b) Hopeful That a New Treatment Will Become Available for Their Vitiligo.	2
Figure S2. Current and/or Previous Treatments or Management Strategies* Reported Among Patients With Vitiligo From EU5 Countries.	3
Figure S3. EU5 Patients (a) Who Had Never Used Prescription Treatment and the Reasons Reported and (b) Who Had Stopped Using Prescription Treatment and the Reasons Reported ...	4

Figure S1. EU5 Patients (a) Not Actively Using Treatment and (b) Hopeful That a New Treatment Will Become Available for Their Vitiligo.



^a $P < 0.05$ vs Germany.

Figure S2. Current and/or Previous Treatments or Management Strategies* Reported Among Patients With Vitiligo From EU5 Countries.



* Patients could select multiple treatments or management strategies. † Medications include vitamins A and D and other oral nonprescription antioxidants, vitamins, or supplements.

Figure S3. EU5 Patients (a) Who Had Never Used Prescription Treatment and the Reasons Reported and (b) Who Had Stopped Using Prescription Treatment and the Reasons Reported

